摘要
有报道一些老年痴呆症模型小鼠携带淀粉样前体蛋白(APP)转基因瑞典型突变,呈现自发性癫痫发作和/或癫痫样脑电活动增加。显型癫痫的主要原因仍在讨论中。相反,淀粉样前体蛋白(APP)转基因瑞典型突变小鼠(APPswe)发展了细胞外淀粉样蛋白斑块,APP的北极型突变小鼠(E693G)没有β-分泌酶裂解的倾向和显示细胞内淀粉样蛋白沉积而不是斑块。我们对3.5个月和8个月龄之间21个APP的北极型突变小鼠APParc的和11个野生型小鼠对照组,进行了全面的长程视频脑电图记录三个为期两周的周期。未检测到APParc小鼠自发性癫痫发作多于野生型对照组小鼠。偶尔检测到APParc小鼠和野生型小鼠长时(1–5s)癫痫样放电,但APParc小鼠比野生型小鼠更多见短期(0.5–< 1s)癫痫样放电。然而,他们平行的记录远比6 个APPswe/PS1dE9小鼠少。在癫痫发作的易感性戊四唑试验里,APParc小鼠表现出比野生型小鼠的尖波放电有更短的潜伏期,但癫痫发作持续时间没有增加。与APPSwe小鼠相比,尽管APP表达程度更高,这些数据代表了APParc小鼠相关的轻度显型癫痫。因此,细胞外淀粉样蛋白斑块或增加的β-分泌酶裂解产物在APPSwe小鼠癫痫显型中显得重要。
关键词: 淀粉样前体蛋白,β淀粉样蛋白,癫痫,脑电图,癫痫样放电,戊四氮
Current Alzheimer Research
Title:Increased Epileptiform EEG Activity and Decreased Seizure Threshold in Arctic APP Transgenic Mouse Model of Alzheimer’s Disease
Volume: 13 Issue: 7
Author(s): Sofya Ziyatdinova, Annica Rönnbäck, Kestutis Gurevicius, Diana Miszczuk, Caroline Graff, Bengt Winblad, Asla Pitkänen and Heikki Tanila
Affiliation:
关键词: 淀粉样前体蛋白,β淀粉样蛋白,癫痫,脑电图,癫痫样放电,戊四氮
摘要: Several Alzheimer model mice carrying transgenic amyloid precursor protein (APP) with the Swedish mutation have been reported to exhibit spontaneous seizures and/or increased epileptiform EEG activity. The primary cause for the epilepsy phenotype is still under debate. In contrast to mice with APPswe mutation that develop extracellular amyloid plaques, mice with APP Arctic mutation (E693G) have no bias toward β-secretase cleavage and display intracellular amyloid deposits but not plaques. We conducted a systematic long-term video-EEG recording in three two-week sessions on 21 APParc and 11 wild-type control mice between 3.5 and 8 months of age. Spontaneous seizures were not detected more often in APParc mice than in their wild-type control mice. Long (1 – 5 s) epileptiform discharges were occasionally detected in both APParc and wild-type mice, but short (0.5 – <1 s) epileptiform discharges were more common in APParc mice than in wild-types. However, they were far less frequent than in 6 APPswe/PS1dE9 mice recorded in parallel. In pentylenetetrazole test for seizure susceptibility, APParc mice displayed a shorter latency to sharp-wave discharges than wildtype mice but no increase in seizure duration. These data speak for a relatively mild epilepsy phenotype in APParc mice compared to APPswe mice despite even higher extent of APP overexpression. Thus extracellular amyloid plaques or increased β-secretase cleavage products appear important for the epilepsy phenotype in APPswe mice.
Export Options
About this article
Cite this article as:
Sofya Ziyatdinova, Annica Rönnbäck, Kestutis Gurevicius, Diana Miszczuk, Caroline Graff, Bengt Winblad, Asla Pitkänen and Heikki Tanila , Increased Epileptiform EEG Activity and Decreased Seizure Threshold in Arctic APP Transgenic Mouse Model of Alzheimer’s Disease, Current Alzheimer Research 2016; 13 (7) . https://dx.doi.org/10.2174/1567205013666160129095508
DOI https://dx.doi.org/10.2174/1567205013666160129095508 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Novel Screening Technologies on Ion Channel Drug Discovery
Combinatorial Chemistry & High Throughput Screening Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study
CNS & Neurological Disorders - Drug Targets Chemistry, Biological Properties and SAR Analysis of Quinoxalinones
Mini-Reviews in Medicinal Chemistry Melatonin, its Metabolites and its Synthetic Analogs as Multi-Faceted Compounds: Antioxidant, Prooxidant and Inhibitor of Bioactivation Reactions
Current Medicinal Chemistry Preface
Current Neuropharmacology Probenecid: An Emerging Tool for Neuroprotection
CNS & Neurological Disorders - Drug Targets Application of Human Placental Villous Tissue Explants to Study ABC Transporter Mediated Efflux of 2,4-Dinitrophenyl-S-Glutathione
Current Pharmaceutical Biotechnology Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing on Neurological Disorders
Venoms and Toxins Experimental Models for the Discovery of Novel Anticonvulsant Drugs: Focus on Pentylenetetrazole-Induced Seizures and Associated Memory Deficits
Current Pharmaceutical Design Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4
Current Medicinal Chemistry Inquiries into the Biological Significance of Transmembrane AMPA Receptor Regulatory Protein (TARP) γ−8 Through Investigations of TARP γ−8 Null Mice§
CNS & Neurological Disorders - Drug Targets Serotonin Control of Dopaminergic Neurotransmission: Focus on 5-HT2 Receptors
Current Neuropharmacology The Effect of Mianserin on Lifespan of <i>Caenorhabditis elegan</i> is Abolished by Glucose
Current Aging Science Efficient High-throughput Techniques for the Analysis of Disease- Resistant Plant Varieties and Detection of Food Adulteration
Current Protein & Peptide Science A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod
Current Neuropharmacology Isoform Selective Voltage-Gated Sodium Channel Modulators and the Therapy of Pain
Current Medicinal Chemistry Genetics and Molecular Biology of Tuberous Sclerosis Complex
Current Genomics Drug Delivery Across the Blood-Brain Barrier
Current Nanoscience